Purpose: Baclofen is widely used off-label for alcohol use disorders (AUD) in France, despite its uncertain efficacy and safety, particularly at high doses. This study was designed to evaluate the safety of this off-label use compared to the main approved drugs for AUD (acamprosate, naltrexone, nalmefene). Results: The cohort included 165 334 patients, 47 614 of whom were exposed to baclofen. Patients exposed to baclofen differed from those treated with approved drugs in terms of sociodemographic and medical characteristics (more females, higher socioeconomic status, fewer hospitalisations for alcohol-related problems), but these differences tended to fade at higher doses of baclofen. Baclofen exposure was signif- Conclusions: This study raises concerns about the safety of baclofen for AUD, particularly at high doses, with higher risks of hospitalisation and mortality than approved drugs.
In France, this use of baclofen has become very popular in the medical community and the general press since the publication of "The End of my Addiction" 8, 9 in 2008, by O. Ameisen, an alcoholic physician popularising his self-case report. 2 French physicians have subsequently prescribed off-label baclofen to several thousands of patients. [10] [11] [12] About 120 000 people initiated drug for AUD each year between 2009 and 2015 in France, with an annual prevalence of 500 000 treated persons. 13 In 2014, the French National Agency for Medicines and Health
Products Safety (ANSM) enacted a temporary authorization for use 14 to monitor this use while awaiting more convincing studies on the efficacy and safety of baclofen for AUD.
Several clinical trials have been conducted in various countries, [15] [16] [17] but no consensus has been reached concerning efficacy, as some trials reported reduced craving and higher abstinence rates, 1, 3, 5, 15 whereas others failed to show any effect. 4, [16] [17] [18] In terms of safety, the adverse effects reported in these trials concerned neurological effects with confusion, seizures, psychiatric disorders, etc. and several serious adverse reactions have been reported by the French pharmacovigilance network and case reports. [19] [20] [21] These studies were not designed to assess the safety of baclofen in terms of all-cause hospitalisation and death, particularly at doses much higher than those recommended for the approved indication. 22, 23 This study was conducted to evaluate the risk of hospitalisation and death (specific and all-cause) of real-life use of baclofen compared to the main approved drugs for AUD.
| MATERIAL AND METHODS

| Data sources
The study was conducted on medical administrative data from the French national health insurance information system database (SNIIRAM) linked to the hospital discharge database (PMSI) and crossed with the Epidemiology Centre on Medical Causes of Death (CépiDc) database. SNIIRAM and PMSI have already been described [24] [25] [26] (see Supporting Information S1) and successfully used in epidemiological and pharmacoepidemiological studies. [27] [28] [29] [30] [31] Data on causes of death are generated in France by CépiDc 32 (see also Supporting Information S1).
| Study population
This study included patients, aged 18 to 70 years, who initiated one of the main approved drugs for AUD (acamprosate, naltrexone, nalmefene) or baclofen between 1 January 2009 and 31 December 2015, with no other reimbursement for these drugs or disulfiram (another drug for AUD, which induces an Antabuse reaction in the case of alcohol intake, and which can only be used in abstinent patients) during the previous 3 years.
Baclofen had to be prescribed for an off-label use. During the 3 years preceding initiation of baclofen, patients with hospitalisation or ongoing severe or costly long-term disease for a neurological condition possibly responsible for painful involuntary muscle spasms (ICD-10 codes: C70-C71, C793-C794, D32-D33, D42-D43, G04-G06,   G09, G114, G12-G13, G24-G26, G31-G32, G35-G37, G46, G80-G83, G91, G93, G95, I60-I64) , reimbursement for wheelchairs or related devices or dantrolene, 10, 11 were therefore identified and excluded from the cohort. The same selection criteria were applied to patients initiating approved drugs.
Patients reimbursed for opioid substitution therapy or hospitalised for a serious alcohol-related disease (eg, alcohol liver disease, chronic pancreatitis, polyneuropathy; codes: E244, G312, G621, G721, I426, K70, K860) during the 3 years preceding inclusion were excluded. Patients with a long-term disease or hospitalised for a disease during the year preceding inclusion, defined as increasing the risk of 1-year mortality according to the Charlson score 33 matched to SNIIRAM data, 34 were also excluded. Approved drugs or baclofen had to be initiated by a physician managing patients for AUD, namely general practitioners, hospital physicians, or psychiatrists. Patients had
KEY POINTS
• Baclofen is widely used off-label for alcohol use disorders in France, despite its uncertain efficacy and safety, particularly at high doses.
• Exposure to baclofen vs approved drugs for alcohol use disorders was associated with an increased risk of hospitalisation and death in a large nationwide observational patient cohort.
• High-dose baclofen were associated with an increased risk of hospitalisation and death.
• These associations particularly concerned drug intoxication (hospitalisation and death) and death from an unknown cause by the physician reporting the death.
to have received at least a second reimbursement for the same drug within 60 days after the first reimbursement.
| Exposure and follow-up
Patients were exposed to only the first drug reimbursed. Patients were assumed to be exposed to fixed doses of approved drugs based on their indications. Patients exposed to baclofen were either considered globally, regardless of whether or not the baclofen dose varied over to 180 mg/day, and ≥180 mg/day (high dose).
Patients were followed for a maximum of 1 year. Follow-up started at the second dispensing and ended at the first of the following events: hospitalisation, death, switch from the initial drug to another drug, end of study (31 December 2015, or 31 December 2014 for the causes of death study), or 60 days after the last dispensing of the same drug.
| Outcomes
Primary outcomes were death from any cause (or hospitalisation followed by death during the following 30 days, considered to be a death at the date of hospitalisation. Deaths occurring more than 30 days after hospitalisation were ignored), and all-cause hospitalisation, except for obstetric or elective day-only hospitalisation.
Secondary outcomes were death due to specific causes (before 31
December 2014, when the cause of death was available) described by main groups of diseases and according to the most frequent underlying cause, deaths by suicide (ICD-10: X60-X84), and hospitalisations for specific causes described by the main groups of diseases and according to the most frequent primary diagnoses.
| Statistical analysis
Patients were compared in terms of the following sociodemographic Risks of specific and all-cause hospitalisation and death were assessed for patients exposed to baclofen vs approved drugs. Patients exposed to baclofen were considered globally, regardless of the mean daily dose reached during follow-up, and were then categorised according to classes of mean daily dose varying over time. The following indicators were used to measure these risks: incidence per 1000
person-years standardised for gender and age structured in 10-year age-groups of the entire cohort, and a hazard ratio (HR) calculated from a Cox model adjusted for gender and age, or fully adjusted (HR f ) for gender, age, deprivation index, speciality of the physician who initiated an approved drug or baclofen, exposure to psychiatric drugs, history of hospitalisation for alcohol-related problems, history of comorbidity, and year of inclusion, for classes of doses varying over time or regardless of the dose for baclofen exposure vs approved drugs.
We repeated our analyses by stratifying our Cox model on one or several adjustment covariates.
Complementary analyses were performed on the subset of patients with a history of hospitalisation for alcohol-related problems, to assess the robustness of the results by studying a more homogeneous subgroup of patients.
3 | RESULTS
| Study population
The study included 165 334 patients: 47 614 (28.8%) exposed to baclofen and 117 720 (71.2%) exposed to approved drugs ( Figure 1 ).
Median follow-up of patients exposed to baclofen or approved drugs was 87 and 81 days, respectively. At the end of follow-up, 45.1% of patients taking baclofen were exposed to a mean daily dose <30 mg/day, 35.9% to 30 to 75 mg/day, 15.3% to 75 to 180 mg/ day, and 3.6% to ≥180 mg/day (Table 1 ).
Patients exposed to baclofen differed from those exposed to approved drugs in terms of sociodemographic and medical characteristics: more likely to be female (43.8% vs 30.8%, respectively), higher socioeconomic status (17.9% vs 13.9% for the least deprived area of residence), lower frequency of history of hospitalisation for alcohol-related problems (12.7% vs 23.5%), and lower frequency of exposure to anxiolytics (44.6% vs 71.6%). With increasing doses, from <30 to ≥180 mg/day, patients exposed to baclofen tended to resemble those receiving approved drugs, particularly in terms of age, gender, history of hospitalisation for alcoholrelated problems, and exposure to anxiolytics (Table 1) .
Among patients with a history of hospitalisation for alcoholrelated problems (33 679), those exposed to baclofen were relatively similar to those exposed to approved drugs in terms of the various characteristics evaluated (Table 2 ).
| Risks of all-cause hospitalisation or death
A total of 16 226 patients (9.8% of the population) were hospitalised and 556 patients (0.34%) died during follow-up. In "gender-age" analysis, standardised incidences per 1000 person-years for patients exposed to baclofen vs approved drugs were lower for all-cause hospitalisation (288 vs 321) and higher for all-cause death (10.8 vs (Table 4) .
Similar results were obtained whether covariates were taken into account by stratification or by adjustment. In particular, models adjusted or stratified for all covariates were similar for both the risks of all-cause hospitalisation and death (Tables S3 and S4 ).
| Primary hospital discharge diagnoses and specific causes of death
Primary hospital discharge diagnoses varied greatly. Several risks were significantly associated with patients treated with baclofen vs approved drugs, particularly, (1) at doses ≥180 mg/day, "injury, poisoning, and certain other consequences of external causes" (codes:
S-T; 17% of hospitalisations) with a HR f = 2.14 [95%CI: (Tables S7 and S8) . 
| Main results
In this study based on a cohort of more than 165 000 patients, exposure to baclofen for AUD was associated with an increased risk of hospitalisation (+13%) and death (+31%) compared to exposure to approved drugs. This association was particularly marked at high doses ≥180 mg/day of baclofen (+46% for hospitalisation and + 117% for death), was also observed for the subset of patients with a history of hospitalisation for alcohol-related problems, and particularly concerned drug intoxication (hospitalisation and death) and unspecified death.
| Comparison with previous studies
This real-life safety cohort study is the first of its kind to examine baclofen used for AUD. The results therefore cannot be directly compared with those of experimental studies, in which, unlike in real-life, patients generally receive treatment within a standardised framework. Our findings concerning specific causes of hospitalisation and death of patients treated with baclofen, highlighting the risks of selfpoisoning, and the increased risk of all-cause hospitalisation and death, are consistent with the results of these studies.
| Strengths and limitations
This study was conducted on almost 47 000 patients living in France, treated with baclofen for AUD, including more than 9000 patients taking mean doses ≥75 mg/day (60 times more patients on high-dose baclofen than in the most powerful clinical trial 18 ). Robust and objective measures were used to detect events (hospitalisations, deaths), as the coding of these events is subject to strict and controlled procedures. [24] [25] [26] No patients were lost to follow-up in this study, which is an important point when assessing serious adverse events. All hospitalised patients and all deaths in France were systematically recorded. Assessment of all-cause mortality was preferred in order to take all beneficial and adverse effects of each drug into account.
The two groups presented different characteristics, as is often the case in observational studies. Patients on baclofen globally presented slightly more favourable medical and social characteristics. The effect of complete adjustment for patient characteristics, especially history of hospitalisation for alcohol-related problems, resulted in a higher estimated risk of all-cause hospitalisation in the baclofen group. Similarly, adjustment also led to an increased risk of death among people exposed to baclofen vs approved drugs for AUD.
This study also comprises several limitations. As is often the case in medical administrative database studies, exposure could only be evaluated based on medication dispensing data, which does not guarantee that the medication was actually taken. Similarly, SNIIRAM dispensing data cannot be used to precisely estimate the doses of medication, as the dosage and number of days of treatment are not directly available, but are calculated. Although the estimates necessary to calculate the mean daily dose are probably adequate to measure a dose effect, they cannot be used to precisely define risk levels. The results presented according to the dose categories used in this study must therefore be interpreted with caution.
Another limitation of SNIIRAM data concerns the absence of detailed socioeconomic variables and the absence of reliable measures of obesity and smoking, suggesting a possible risk of residual confounding related to these variables.
The off-label indication for baclofen cannot be determined directly from the SNIIRAM database. Following mediatisation of the use of baclofen for AUD and in view of its central neurological action, the rare use of baclofen has also been reported in bulimia, 37 cocaine addiction and stuttering. 38 Some patients treated with baclofen may also have been included in the cohort for muscle contractures secondary to sciatica, despite the exclusion of private rheumatologist-initiated treatments, which could explain the increased risk of hospitalisation, mainly at low doses <30 mg/day, for dorsalgia (code: M54), or pain (code: R52). However, the low frequency of these hospitalisations possibly not related to the consequences of AUD would have a negligible impact on estimation of the risks of all-cause hospitalisation and death.
The risks associated with all-cause "hospitalisation" and "death" The main limitation of this study is the lack of data about alcohol.
Data concerning the types and severity of alcoholism and alcohol consumption were not available in the SNIIRAM database (only hospital stays for alcohol-related problems were identified), and the indications for each drug for AUD, unknown, can range from abstinence to reduction of alcohol consumption or craving. Baclofen for AUD is an offlabel drug promoted by patients and prescribers, unlike approved drugs. AUD could differ depending on these drugs, as the medical care of patients could temper the strength of risk associations and, more specifically, the dose-response relationship.
However, baclofen exposure increased the risks of hospitalisation or death, irrespective of the dose class, and the similarity of the main results in the more homogeneous population restricted to subjects with a history of hospitalisation for alcohol-related problems, supports the absence of major residual confounding in this population of patients, under the age of 70 years, with no major comorbidities.
| Conclusion
This study raises concerns about the safety profile of baclofen for AUD, particularly at high doses, with higher risks of hospitalisation and mortality than approved drugs.
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